← Back to screener

NEUROCRINE BIOSCIENCES INC NBIX

Rank #1450 · Nasdaq · $14.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
48.0
P/E
58.8
P/B
8.60
ROE
14.6%
Op. Margin
13.3%
Debt Ratio
66%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 58.8x, P/B 8.60x. Ranks in the top 66% of the universe.

Profitability ★★★☆☆
Good

ROE 14.6%. Ranks in the top 33% of the universe.

Safety ★★★★☆
Good

Debt ratio 66%. Ranks in the top 28% of the universe.

Growth ★★★★☆
Excellent

Revenue growth of 26.8% year over year. Ranks in the top 13% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.1B$-0.1B$0.0B-1817.5340
2012$0.0B$-0.0B$-0.0B$0.0B-41.01980
2013$0.1B$0.0B$0.0B$0.0B43.8215
2014$0.1B$0.0B$0.0B$0.1B2.757
2015$0.0B$-0.0B$-0.0B$0.2B-1701.922
2016$0.0B$-0.1B$-0.1B$0.1B–42
2017$0.0B$-0.1B$-0.1B$0.2B-476.524
2018$0.0B$-0.1B$-0.1B$0.4B-982.5105
2019$0.2B$-0.1B$-0.1B$0.3B-81.3163
2020$0.5B$0.0B$0.0B$0.4B8.2180
2021$0.8B$0.1B$0.0B$0.5B9.2127
2022$1.0B$0.2B$0.4B$0.6B15.6110
2023$1.1B$0.1B$0.1B$1.1B9.059
2024$1.5B$0.2B$0.2B$1.4B16.774
2025$1.9B$0.3B$0.2B$1.7B13.366

← See the full screener